Elba Llop
Overview
Explore the profile of Elba Llop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rivera-Esteban J, de la Iglesia Garcia D, Agudo-Castillo B, Calleja J, Llop E
Endoscopy
. 2025 Feb;
57(3):295.
PMID: 40010318
No abstract available.
2.
Yip T, Lee H, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al.
J Hepatol
. 2025 Jan;
PMID: 39863175
Background & Aims: Current guidelines recommend a 2-step approach for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with Fibrosis-4 index (FIB-4) followed by liver stiffness measurement...
3.
Fortea J, Alvarado-Tapias E, Simbrunner B, Ezcurra I, Hernandez-Gea V, Aracil C, et al.
J Hepatol
. 2024 Dec;
PMID: 39701300
Background & Aims: Data on the effectiveness of classical non-selective beta-blockers (cNSBBs, i.e., propranolol and nadolol) vs. carvedilol in patients with cirrhosis are scarce. In the present study, we aimed...
4.
Abad J, Llop E, Arias-Loste M, Burgos-Santamaria D, Martinez Porras J, Iruzubieta P, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39694202
Metabolic dysfunction-associated steatohepatitis(MASH) is commonly seen in biopsy proven steatotic liver disease(SLD). Life-style intervention reaching a weight loss higher than 10% promotes MASH resolution, but this goal is only achieved...
5.
Perez-Campuzano V, Rautou P, Marjot T, Praktiknjo M, Alvarado-Tapias E, Turco L, et al.
JHEP Rep
. 2024 Nov;
6(12):101191.
PMID: 39583091
Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients...
6.
Feng G, Mozes F, Ji D, Treeprasertsuk S, Okanoue T, Shima T, et al.
Clin Gastroenterol Hepatol
. 2024 Oct;
PMID: 39362618
Background & Aims: Metabolic dysfunction-associated steatohepatitis (MASH) and fibrotic MASH are significant health challenges. This multi-national study aimed to validate the acMASH index (including serum creatinine and aspartate aminotransferase concentrations)...
7.
El Hajra I, Llop E, Blanco S, Perello C, Fernandez-Carrillo C, Calleja J
J Clin Med
. 2024 Sep;
13(18).
PMID: 39337086
Multiple studies have linked COVID-19 to a higher incidence of thromboembolic disorders. However, the association of COVID-19 with other potentially life-threatening complications, such as splanchnic vein thrombosis, is less well...
8.
Jachs M, Odriozola A, Turon F, Moga L, Tellez L, Fischer P, et al.
Lancet Gastroenterol Hepatol
. 2024 Sep;
9(12):1111-1120.
PMID: 39326431
Background: In patients with compensated advanced chronic liver disease (cACLD), risk of clinically significant portal hypertension (CSPH) can be estimated by applying non-invasive tests such as liver stiffness measurement (LSM),...
9.
Magaz M, Giudicelli-Lett H, Abraldes J, Nicoara-Farcau O, Turon F, Rajoriya N, et al.
J Hepatol
. 2024 Aug;
82(1):72-83.
PMID: 39181213
Background & Aims: Current knowledge of the natural history of patients with porto-sinusoidal vascular disorder (PSVD) is derived from small studies. The aim of the present study was to determine...
10.
Zhou X, Kim S, Yip T, Petta S, Nakajima A, Tsochatzis E, et al.
Gut
. 2024 Aug;
73(11):1883-1892.
PMID: 39089860
Background: Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD). Aim: To explore the effects of statins on the long-term risk of all-cause mortality, liver-related clinical events...